What Is Melatonin? (Sleep Hormone Mechanisms)

Most people think melatonin's only job is to make you drowsy at night. That's not quite right. Melatonin is the master regulator of circadian timing—it doesn't induce sleep directly, but signals to every tissue in your body that darkness has arrived and metabolic, hormonal, and neurological processes should shift accordingly. Without melatonin, your liver, kidneys, heart, and brain would each run on slightly different internal clocks, creating metabolic chaos.

We've worked with researchers studying chronobiology for years. The gap between what supplement labels claim and what melatonin actually does in the body is wider than most people realize.

What is melatonin and how does it work in the body?

Melatonin is a neurohormone synthesized primarily in the pineal gland from the amino acid tryptophan, released in response to darkness to regulate circadian rhythm, body temperature, immune function, and reproductive hormones by binding to MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus. Peak secretion occurs between 2–4 AM, with levels typically ranging from 80–120 pg/mL during the day to 60–150 pg/mL at night in healthy adults.

Melatonin Synthesis and Regulation Pathways

Melatonin production follows a highly regulated four-step enzymatic pathway. The process begins with tryptophan, an essential amino acid obtained through diet. Tryptophan is first converted to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase, then to serotonin by aromatic L-amino acid decarboxylase. Serotonin is converted to N-acetylserotonin by arylalkylamine N-acetyltransferase (AANAT)—the rate-limiting enzyme that determines melatonin output. Finally, hydroxyindole-O-methyltransferase (HIOMT) converts N-acetylserotonin into melatonin.

This pathway is controlled by the suprachiasmatic nucleus (SCN), a cluster of approximately 20,000 neurons located in the anterior hypothalamus directly above the optic chiasm. The SCN receives light input from specialized retinal ganglion cells containing melanopsin, a photopigment most sensitive to blue light at 480 nm wavelength. When melanopsin detects light, it sends inhibitory signals to the SCN, which suppresses AANAT activity in the pineal gland—effectively blocking melatonin synthesis during daylight hours.

As darkness falls and melanopsin stops detecting light, the SCN removes its inhibitory signal. The superior cervical ganglion releases norepinephrine, which binds to beta-adrenergic receptors on pinealocytes (pineal gland cells), activating AANAT and triggering melatonin synthesis within 2–3 hours of darkness onset. Melatonin is lipophilic, meaning it doesn't require vesicular transport—it diffuses directly through cell membranes into circulation immediately after synthesis.

Once in the bloodstream, melatonin has a short half-life of 20–50 minutes. It is rapidly metabolized in the liver by cytochrome P450 enzymes (primarily CYP1A2) into 6-hydroxymelatonin, which is then conjugated with sulfate or glucuronide and excreted in urine. This rapid clearance is why melatonin levels drop sharply after sunrise—the pineal gland stops producing it, and hepatic metabolism clears what remains within 1–2 hours.

Melatonin Receptor Mechanisms and Circadian Synchronization

Melatonin exerts its effects by binding to two G-protein-coupled receptors: MT1 (melatonin receptor 1A) and MT2 (melatonin receptor 1B). Both are located throughout the central nervous system and peripheral tissues, but their highest concentrations are in the SCN, where they regulate the master circadian clock.

MT1 receptor activation inhibits neuronal firing in the SCN, effectively silencing the wake-promoting signals that dominate during the day. This doesn't cause immediate sedation—it permits the transition to sleep by removing the active arousal mechanisms that keep you awake. Think of it as releasing the brake rather than stepping on the gas. MT2 receptor activation phase-shifts the circadian clock itself, advancing or delaying the timing of circadian rhythms depending on when melatonin is administered. This is why exogenous melatonin taken in the late afternoon can shift your circadian rhythm earlier (useful for eastward travel), while morning administration can delay it (useful for westward travel or delayed sleep phase disorder).

Beyond the SCN, melatonin receptors are found in the retina, cardiovascular system, immune cells, gastrointestinal tract, and reproductive organs. In the retina, melatonin regulates photoreceptor disc shedding and dopamine release, synchronizing visual sensitivity to the light-dark cycle. In the cardiovascular system, MT2 receptors mediate vasodilation, contributing to the nocturnal dip in blood pressure observed in healthy individuals—nighttime blood pressure typically drops 10–20% below daytime levels, a phenomenon impaired in shift workers and individuals with circadian misalignment.

Melatonin also regulates body temperature through hypothalamic thermoregulatory centers. Core body temperature drops approximately 0.3–0.5°C during the night, reaching its nadir around 4–5 AM—this decline is melatonin-dependent. When melatonin secretion is suppressed by bright light exposure at night, the normal temperature drop is blunted, which impairs sleep initiation. The vasodilatation in distal skin (hands and feet) that redistributes heat away from the core is mediated by melatonin signaling, which is why cold extremities can delay sleep onset.

Factors That Suppress or Enhance Melatonin Production

Light exposure is the dominant regulator of melatonin synthesis, and the relationship varies with light intensity and wavelength. Blue light (450–480 nm) suppresses melatonin far more effectively than longer wavelengths—a 2011 study published in The Journal of Clinical Endocrinology & Metabolism found that 2 hours of blue-enriched light at 460 nm suppressed melatonin by 88%, while red light at 620 nm suppressed it by only 18%. This explains why electronic screens (smartphones, tablets, computer monitors) with blue-heavy LED backlighting are particularly disruptive to melatonin secretion when used within 2–3 hours of bedtime.

Lux intensity matters as well. Bright light above 1,000 lux almost completely suppresses melatonin within 30 minutes, while dim light below 50 lux has minimal effect. Standard indoor lighting ranges from 100–500 lux—sufficient to partially suppress melatonin if exposure occurs in the evening. A 2001 randomized controlled trial published in The Journal of Physiology demonstrated that even 200 lux of white light exposure for 90 minutes before bed reduced melatonin concentrations by 71% and delayed sleep onset by 85 minutes on average.

Age significantly impacts melatonin production. Peak melatonin output occurs during childhood and adolescence, with nighttime levels reaching 120–200 pg/mL. After age 40, nocturnal melatonin secretion declines by approximately 10% per decade—adults over 70 typically produce 50–60% less melatonin than young adults. This decline correlates with increased sleep fragmentation, earlier wake times, and reduced slow-wave sleep observed in older populations. The mechanism involves calcification of the pineal gland (accumulation of calcium phosphate deposits called corpora araceana), which reduces functional pinealocyte density.

Caffeine consumption affects melatonin indirectly through adenosine receptor antagonism. Adenosine accumulates during wakefulness and promotes sleep pressure by inhibiting wake-promoting neurons. Caffeine blocks adenosine receptors, reducing homeostatic sleep drive and indirectly suppressing melatonin onset. A 2015 double-blind study published in Science Translational Medicine found that 200 mg of caffeine (approximately one strong coffee) consumed 3 hours before habitual bedtime delayed melatonin onset by 40 minutes—comparable to the delay caused by bright light exposure.

Alcohol acutely suppresses melatonin secretion during the absorption phase. A study in Alcoholism: Clinical and Experimental Research showed that alcohol consumed in the evening reduced nocturnal melatonin levels by 15–19%, with suppression lasting 2–3 hours post-consumption. The mechanism involves disruption of pineal sympathetic innervation and altered serotonin metabolism, which reduces substrate availability for melatonin synthesis.

Melatonin: Supplement Formulation Comparison

What If: Melatonin Scenarios

What If I Take Melatonin but Still Can't Fall Asleep?

The light environment is a key factor, since bright light exposure can entirely counteract melatonin's effects. Exposure to a bright screen or a well-lit room alongside exogenous melatonin allows melanopsin-mediated suppression to override it. Circadian signaling occurs at levels well below the quantities contained in most commercial supplements. Larger amounts do not produce proportionally stronger effects and have been linked to next-day grogginess attributed to residual receptor occupancy. When melatonin does not improve sleep latency, the underlying issue may not be circadian misalignment but hyperarousal, sleep apnea, or another sleep disorder that melatonin does not address.

What If My Melatonin Levels Are Naturally Low?

If salivary or urinary melatonin metabolite testing confirms low nocturnal melatonin (common in shift workers, older adults, or individuals with pineal calcification), exogenous supplementation can restore circadian signaling. Use dim-light melatonin onset (DLMO) testing to determine your natural melatonin rise time—supplementation should be timed 2–3 hours before this point to phase-advance your rhythm, or at your habitual bedtime if maintaining current timing. Low melatonin without circadian misalignment symptoms may not require intervention—some individuals maintain normal sleep with lower melatonin levels due to compensatory mechanisms in other circadian pathways. Address light hygiene first: eliminate blue light exposure after sunset, increase daytime bright light (ideally 10,000+ lux within 1 hour of waking), and maintain consistent sleep-wake schedules to optimize endogenous production before adding supplements.

What If I'm Using Melatonin for Jet Lag?

The timing of melatonin administration determines whether it advances or delays your circadian rhythm. For eastward travel (requiring phase advance), take 0.5–3 mg melatonin in the late afternoon or early evening at your destination—this signals your SCN to shift your clock earlier. For westward travel (requiring phase delay), melatonin is less effective because taking it in the early morning (when needed to delay the clock) conflicts with light exposure and is often impractical. Instead, focus on timed bright light exposure: morning light delays your rhythm, evening light advances it. Combine melatonin with strategic light exposure for maximum entrainment speed—most people require 1 day of adjustment per 1–1.5 time zones crossed when using both tools together. Larger amounts of melatonin for jet lag have been associated with increased next-day sedation without improved circadian adjustment.

What If I'm Considering Long-Term Melatonin Use?

Melatonin is not reported to cause physiological dependence or to suppress endogenous production at replacement levels. Long-term studies spanning 6–24 months show no tolerance development or withdrawal symptoms upon discontinuation. However, chronic use of large amounts may desensitize MT1 and MT2 receptors, reducing responsiveness over time. Circadian hygiene factors described in the literature include consistent sleep-wake times, morning bright light exposure, evening light restriction, and a cool sleeping environment. Loss of responsiveness after prolonged nightly use has been attributed to receptor desensitization, with washout periods described as a way of restoring receptor sensitivity. Long-term safety data for melatonin is robust—meta-analyses of randomized controlled trials show no serious adverse events with continuous use up to 2 years—but it remains a tool to support circadian alignment, not a substitute for addressing underlying causes of sleep disruption.

The Physiological Truth About Melatonin

Here's the honest answer: melatonin supplements are wildly overused for conditions they don't treat. If your sleep problem is anxiety, restless legs, sleep apnea, or chronic pain, melatonin won't fix it—those are arousal or structural sleep disorders, not circadian timing disorders. Melatonin works for delayed sleep phase disorder, jet lag, shift work adjustment, and age-related circadian rhythm weakening. It does not work as a general sedative.

The amount matters more than the marketing suggests. Most commercial supplements contain substantially more melatonin than the amount corresponding to natural nighttime secretion. Higher amounts saturate receptors without additional benefit and increase the likelihood of next-day grogginess, vivid dreams, and receptor desensitization with chronic use. A 2001 study published in Sleep Medicine Reviews found that 0.3 mg was as effective as 3 mg for sleep onset and circadian phase-shifting, with fewer side effects.

The supplement industry's quality control is inconsistent at best. A 2017 analysis published in the Journal of Clinical Sleep Medicine tested 31 melatonin supplements and reported that actual melatonin content ranged from −83% to +478% of the labeled amount, with some products containing almost no melatonin and others nearly five times the stated amount. Lot-to-lot variability within the same brand was common. If using melatonin for research or therapeutic purposes, choose products with third-party testing (USP, NSF, or ConsumerLab certification) to verify content accuracy.

Melatonin is not a sleep aid in the pharmaceutical sense—it's a chronobiotic, meaning it shifts or reinforces circadian timing. If your circadian rhythm is already aligned with your desired sleep schedule and you still can't sleep, adding melatonin won't help. Fix your light environment, caffeine timing, and sleep hygiene first. Use melatonin only when the problem is demonstrably circadian.

Melatonin remains one of the most studied compounds in chronobiology and sleep research, particularly in the context of circadian misalignment rather than insomnia broadly defined. The difference between effective and ineffective use comes down to understanding what melatonin actually does: it tells your body what time it is, not whether to be asleep or awake. That distinction matters more than most people realize.

At Real Peptides, we focus on providing research-grade compounds with verified purity for biological research applications. Our catalog includes peptides like Pinealon, a pineal gland bioregulator studied for its potential neuroprotective and circadian-supportive properties, and Epithalon, a tetrapeptide investigated for its effects on melatonin secretion and circadian rhythm regulation in aging models. You can explore our full range of high-purity peptides at Real Peptides to find the right tools for your research into circadian biology, neuroprotection, and beyond.

The most common mistake with melatonin isn't the supplement itself—it's expecting it to solve a problem it was never designed to address.

What exactly is melatonin, and why is it catalogued alongside research peptides?

Melatonin is N-acetyl-5-methoxytryptamine, a small indoleamine derived from tryptophan by way of serotonin. Chemically it is not a peptide at all — it carries no amide backbone of linked amino acids — yet it is routinely stocked and catalogued next to peptide inventories because laboratories studying circadian biology, oxidative stress, and neuroendocrine signaling often work across both categories. Its molecular weight is 232.28 g/mol, far smaller than the chains described in general overviews of research peptides, and that small, lipophilic structure is what allows it to cross membranes and reach intracellular compartments readily.

In research inventories, melatonin is typically supplied as a white to off-white crystalline powder rather than a lyophilized cake, which distinguishes its handling from peptide material such as thymic fractions discussed under what thymosins do. Because it binds high-affinity G protein-coupled receptors and also acts through receptor-independent redox chemistry, it appears in study designs spanning sleep-wake research, seasonal reproduction models, and anti-aging and longevity research compounds. Laboratories sourcing it should follow the same documentation and handling standards outlined in best research practices for melatonin. All material of this kind is intended for in vitro and preclinical laboratory use only.

How should lyophilized or crystalline melatonin be stored in a laboratory?

Melatonin in dry powdered or lyophilized form is comparatively stable when kept cold, dark, and dry. Standard practice is storage at −20 °C in a tightly sealed, light-resistant vial with desiccant, protected from humidity cycling that can cause clumping and surface hydrolysis of trace impurities. The compound is photosensitive: its indole ring and 5-methoxy group make it vulnerable to UV-driven degradation, so amber glass or foil-wrapped containers are preferred on the bench as well as in the freezer. These controls mirror the general cold-chain discipline described in best research practices for melatonin.

Once a stock solution exists, stability drops sharply relative to dry material. Solutions are generally kept frozen in single-use aliquots to avoid repeated freeze-thaw, and solvent choice matters because melatonin is poorly water-soluble and far more soluble in ethanol or DMSO. Compatibility questions of this type are covered more broadly in what you should not combine peptides with. Visual inspection is also informative — clear, particulate-free solutions are expected, in the same way researchers assess appearance for other compounds such as in what Adamax looks like in solution. Logging lot number, receipt date, and freezer position supports reproducibility across repeated experiments.

What analytical methods confirm melatonin purity and identity?

Reversed-phase high-performance liquid chromatography (HPLC) with UV detection near 222–280 nm is the workhorse assay for melatonin purity, since the indole chromophore absorbs strongly and resolves cleanly from its common process-related relatives such as N-acetylserotonin, 5-methoxytryptamine, and residual tryptophan derivatives. A credible purity figure is reported as area percent at a stated wavelength with the gradient and column chemistry disclosed, not as an unsupported number. Mass spectrometry — typically LC-MS or LC-MS/MS with electrospray ionization — confirms identity through the expected protonated molecular ion and characteristic fragment ions, distinguishing melatonin from isobaric or near-isobaric contaminants.

Supporting tests may include nuclear magnetic resonance for structural confirmation, Karl Fischer titration or loss-on-drying for water content, and residual solvent screening by headspace gas chromatography. Heavy metal and microbial limits are also common on analytical packages. The same evidence hierarchy applies across the catalog, whether evaluating indoleamines or chains described in what research peptides are and healing and recovery peptide mechanisms. Buyers unsure how to interpret raw chromatograms will find orientation in how to tell if a peptide supplier is legitimate and in best research practices for melatonin.

What should a melatonin certificate of analysis actually contain?

A usable certificate of analysis (COA) is lot-specific and traceable, not a generic marketing document. It should name the compound and CAS identifier, state the batch or lot number, give the manufacture and retest dates, and report purity with the analytical method attached — ideally with the actual HPLC chromatogram and mass spectrum appended rather than a bare percentage. Appearance, water content, and residual solvent data strengthen the record. Where a third-party laboratory performed the testing, the report should carry that laboratory's name and identifiers so results can be independently verified.

Red flags include COAs with no lot number, documents whose dates never change across shipments, purity claims unaccompanied by a chromatogram, or spectra whose peaks do not match the stated molecular weight. The evaluation framework is the same one applied to any compound class, from metabolic research peptides to cognitive and nootropic research peptides. Supplier-level due diligence — business transparency, consistent labeling, documented storage conditions — is discussed in how to tell if a peptide supplier is legitimate. Keeping a COA archive alongside experimental records is simply good laboratory hygiene and supports reproducibility when results are compared across lots.

What is the research history behind the discovery of melatonin?

Melatonin was isolated in the late 1950s from bovine pineal tissue by dermatologist Aaron Lerner and colleagues, who were searching for a pineal factor capable of lightening amphibian skin by aggregating melanin granules in melanophores. That skin-lightening bioassay gave the molecule its name and explains why early literature framed it primarily as a pigmentation factor rather than a circadian signal. Its structure as N-acetyl-5-methoxytryptamine was established shortly thereafter, and the biosynthetic route from tryptophan through serotonin was mapped over the following decade.

The pigmentation thread is historically interesting because it places melatonin in the same early research lineage as melanocortin work, later represented by compounds covered in best research practices for Melanotan 1 and in reviews of skin anti-aging research peptides. Attention shifted decisively in the 1960s and 1970s, when researchers demonstrated that pineal melatonin output follows a light-entrained rhythm, reframing the molecule as a nocturnal timing signal. Receptor cloning in the 1990s identified MT1 and MT2 subtypes and established melatonin as a pharmacological target rather than a curiosity. Modern interest extends into free-radical chemistry and the territory described in anti-aging and longevity research compounds and what research peptides are.

What does preclinical research report about melatonin's antioxidant activity?

Beyond its receptor-mediated actions, melatonin has been studied extensively as a direct and indirect redox-active molecule. Its electron-rich indole ring can scavenge reactive oxygen and nitrogen species, and several of its oxidation products — including cyclic 3-hydroxymelatonin and N1-acetyl-N2-formyl-5-methoxykynuramine — are themselves reported in the literature as redox-active, giving rise to the concept of a cascade in which one parent molecule neutralizes multiple radicals. Published preclinical work also describes upregulation of endogenous antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, and catalase in various tissue and cell models.

Because it is both lipophilic and partly water-soluble, melatonin distributes into mitochondria and nuclei, which is why mitochondrial oxidative-stress models feature prominently in this literature. Research designs frequently pair it with thiol-based systems, and readers comparing redox tools may find the overview of glutathione ingredients a useful contrast. Overlap with tissue-protection research means melatonin also appears in studies adjacent to healing and recovery peptide mechanisms and to compounds surveyed in anti-aging and longevity research. Methodological consistency — controlled light exposure, fresh solutions, documented lot purity — is emphasized in best research practices for melatonin, since oxidized stock can confound redox endpoints.

How does melatonin compare with peptide research compounds in the same catalog?

The clearest difference is structural. Melatonin is a single small indoleamine with no peptide bonds, while catalog neighbors such as growth hormone secretagogues or thymic fractions are amino acid chains with defined sequences and folding behavior. That distinction drives nearly everything downstream. Peptides are vulnerable to proteolysis, aggregation, and adsorption to container surfaces; melatonin is instead vulnerable to light and oxidation. Peptides are characterized partly by sequence confirmation and amino acid analysis, whereas melatonin characterization relies on chromatographic retention, mass confirmation, and NMR.

Mechanistically, melatonin acts at MT1 and MT2 G protein-coupled receptors and through receptor-independent redox chemistry, while compounds reviewed under growth hormone secretagogue peptides engage the ghrelin receptor system, and thymic material described in what creates thymosin operates through immunomodulatory pathways. Half-life profiles differ too: melatonin clears rapidly via hepatic 6-hydroxylation by CYP1A2, a route with no analogue in peptide catabolism.

Practically, the two classes share documentation standards — lot-specific COAs, cold storage, and verified sourcing — and share the research-use-only framing described in what research peptides are and in supplier evaluation guidance at how to tell if a peptide supplier is legitimate.

What is the regulatory status of melatonin for laboratory purchasers?

Melatonin occupies an unusual regulatory position compared with most compounds in a research catalog. In the United States it has long been marketed as a dietary supplement under the Dietary Supplement Health and Education Act framework, while in a number of other jurisdictions — including much of the European Union, Australia, and the United Kingdom — it is regulated as a prescription medicine. That asymmetry means import, labeling, and resale rules vary substantially by destination, and buyers shipping internationally should confirm local classification before ordering.

Research-grade melatonin sold through peptide and chemical suppliers is a separate matter again: it is offered as analytical or laboratory material, not as a consumable product, and is labeled for in vitro and preclinical investigation only. It is not a controlled substance in the United States. The broader compliance environment governing how research chemicals are marketed and shipped is outlined in research peptide legality and FDA rules, which applies equally to melatonin and to peptide classes such as weight loss and metabolic research peptides.

Institutional purchasers should retain COAs, supplier correspondence, and storage logs. Guidance on vetting vendors appears in how to tell if a peptide supplier is legitimate and in best research practices for melatonin.

What melatonin receptor analogs and related ligands appear in the literature?

Several synthetic ligands have been developed around the MT1/MT2 pharmacophore, and research catalogs often reference them for comparison. Ramelteon, tasimelteon, and agomelatine are the best known receptor agonists, each modifying the indole scaffold or replacing it with a naphthalene or benzofuran core to alter receptor selectivity and metabolic stability. Agomelatine additionally carries 5-HT2C antagonist activity, which illustrates how closely the melatonergic and serotonergic chemical spaces overlap — unsurprising given that serotonin is melatonin's direct biosynthetic precursor. Antagonist tools such as luzindole and 4-P-PDOT are widely used in receptor pharmacology to distinguish MT1- from MT2-mediated effects, and their use is standard when attributing an observed outcome to receptor engagement rather than redox chemistry.

Melatonin also has endogenous metabolites with their own reported activity, including 6-hydroxymelatonin and the kynuramine derivatives. For researchers mapping neuroendocrine signaling across compound classes, the mechanistic contrast with cognitive and nootropic research peptides and with metabolic research peptides is informative, since those operate through entirely different receptor families. Analytical separation of melatonin from its analogs and metabolites requires validated chromatography, which is why the method documentation discussed in best research practices for melatonin matters for comparative work.